#### Supplementary Figure 1: Composition of clinical cohort



**d** Correlation of HGP with time of metastasis diagnosis



**f** Cohort stratified for HGP and RAAS treatment status



n= 84 n= 141

Male

**e** Correlation of HGP with the gender

Female



## **g** Neoadjuvant treated subcohort stratified for HGP and RAAS treatment status



(a) Dot plot: Distribution of percentual HGP in clinical cohort (n=225). (b) Kaplan-Meier curves: OS after CRCLM resection depending on the HGP and treatment naive status (n=121). (c) Kaplan-Meier curves: OS after CRCLM resection depending on the HGP and neoadjuvant treatment status (n=104). (d) Bar plots: Prevalence of rHGP and dHGP in synchronous and metachronous CRCLM (n=220). (e) Bar plots: Prevalence of rHGP in the female and male subgroup (n=215) (f) Kaplan-Meier curves: OS after CRCLM resection depending on the HGP and the application of RAAS-I (n=225). (g) Kaplan-Meier curves: OS after CRCLM resection depending on the HGP and the application of RAAS-I in the neoadjuvant treated subgroup (n=104). P values were calculated by two-sided log-rank test.

#### Supplementary Figure 2: Patient-wise clustering of spots in spaRNA-seq data set



(a) t-SNE plot: 4,857 spots of PT55 (dHGP) clustered via unsupervised Louvain clustering and biologically annotated, H&E staining of PT55 and overlayed Louvain-clustering. (b) Heatmap of 50 uniquely upregulated genes per cluster. (c) t-SNE plot: 4,550 spots of PT68 (dHGP) clustered via unsupervised Louvain clustering and biologically annotated, H&E staining of PT68 and overlayed Louvain-clustering. (d) Heatmap of 50 uniquely upregulated genes per cluster (e) t-SNE plot: 3,890 spots of PT36 (rHGP) clustered via unsupervised Louvain clustering and biologically annotated, H&E staining of PT36 and overlayed Louvain-clustering. (f) Heatmap of 50 uniquely upregulated genes per cluster. (g) t-SNE plot: 2,843 spots of PT44 (rHGP) clustered via unsupervised Louvain clustering and biologically annotated, H&E staining of PT44 and overlayed Louvainclustering. (h) Heatmap of 50 uniquely upregulated genes per cluster. (i) t-SNE plot: 21,804 spots of all patients annotated for patient of origin. (j) t-SNE plot: 21,804 spots of all patients biologically annotated. (k) Bar plots: normalized distribution of tissue types per specimen. (I) Upset plot visualization highlighting the number of genes commonly expressed in all 6 cancer areas. (m) Upset plot visualization highlighting the number of genes commonly expressed in all 6 hepatocyte areas.



(a) t-SNE plot: 22,419 analyzed cells from tumor and corresponding healthy liver clustered via unsupervised Louvain clustering and biologically annotated.
(b) t-SNE plots: canonical marker genes per identified cell population.
(c) Heatmap showing expression of canonical marker genes per cluster.
(d) Heatmap showing 10 highest uniquely upregulated genes per cluster.
(e) Correlation heatmap of annotated clusters, hierarchical clustering location for row and column.
(f) Bar plots: Phenotype percentages normalized to proportions of the total detected cells per patient.

### Supplementary Figure 4: Subclustering of cancer cells from scRNA-seq data set



C Unique upregulated marker genes



**b** Marker gene expression Ċ f ŧ T ÷ ė B2M • 6 É PT54 - ARID3A PT44 - HSPA1A PT61 - MCE2L d Cluster correlation **e** Normalized phenotype expression РТ44 3,1% 96,9% PT54 0,2% 99,8% PT54 activated 21,8% 78,2% mixec 100% PT61 99,9% 0,1% PT61 activated PT52 PT59 rHGP **D** PT55

(a) t-SNE plot: 8,803 cells, previously identified as cancer cells, clustered via unsupervised Louvain clustering and biologically annotated. (b) Box plots and t-SNE plots: quantification for canonical marker genes of the biologically annotated clusters in Louvain clustering. (c) Heatmap showing 10 highest uniquely upregulated genes per cluster. (d) Correlation heatmap of annotated clusters, hierarchical clustering location for row and column. (e) Bar plots: Phenotype percentages normalized to proportions of the total detected cells per patient.

**D** PT61

PT44

# Supplementary Figure 5: Expression of metabolic genes in cancer cells from scRNA-seq data set



(a) Dot plot: significant differentially expressed genes between cancer cells from both HGPs in scRNA-seq data set, involved in glycolysis and PPP, mapped with expression percentages. (b) Pathway mapping: significant differentially expressed genes between cancer cells from both HGPs in scRNA-seq data set, mapped according to the KEGG pathway, color coded according to scaled log fold change values.